CapitalGainsReport: Four Stocks With Big Breakout Potential (EPAZ, TSPG, AITX, NWBO)

Stocks increased on Monday as traders prepared for a busy week of earnings and speculated about a potential slowdown in Federal Reserve interest rate increases.

Investors have begun weighing the possibility that the Fed is preparing to slow the pace of its inflation-fighting rate hikes after months of aggressive tightening.

The OTC market action on Monday was positive, with 9 of the 7 OTC indexes trading higher. With that in mind, let’s take a look at a few stocks that have the potential to breakout with investors taking more interest in the market.

Here are a few stocks that may be poised to have potential breakouts in the upcoming trading sessions.

Epazz Inc. (OTC: EPAZ) is a leading provider of drone technology, blockchain mobile apps, and cloud-based business software solutions.

The company revealed last week that it is upgrading its artificial intelligence-based predictive automation software in current and subsequent productions of the ZenaDrone 1000 aerial technology.

ZenaDrone, Inc. is a provider of multi-purpose unmanned aerial systems with AI technology, multi-spectral sensors, and machine-learning systems.

Epazz ZenaDrone plans to improve the artificial intelligence capabilities of the ZenaDrone 1000 this year. The updates include autonomous navigation of unmapped terrain, deep learning algorithms for various actions, and dual-use features to accommodate commercial and military drone usage.

CEO Shaun Passley, Ph.D., commented: “We will upgrade all our current and future drones with predictive AI to enhance the ZenaDrone 1000’s navigation, sensors, and autonomous flights.”

The ZenaDrone 1000’s autonomous capabilities will be improved by the integration of predictive AI technology, enabling the drone to complete aerial missions using real-time data acquisition and processing to make predictions with less assistance from human drone operators.

Following the announcement, the stock increased by 6.67%. Keep EPAZ on your radar for a potential breakout.

TGI Solar Power Group, Inc. (OTC: TSPG) is a diversified holding company. TGI’s strategy is to acquire innovative and patented technologies, components, processes, designs, and methods with commercial value that will give it a competitive market advantage and generate shareholder value.

The company recently announced the closing of its business combination with Shelly North Carolina, Inc. The two companies will look to finalize the deal as soon as the requisite due diligence reviews have been completed.

As part of the combination strategy, Mr. Val will resign as TGI’s Chief Executive, and Mr. Philippe Machuel, CEO of Shelly, will take over the position of CEO of TGI as well as join the Board of Directors.

The stock dropped 4.65% on Monday, though it had some momentum behind it throughout the day.

Keep TSPG on your watchlist for stocks poised to bounce in the upcoming days.

Artificial Intelligence Technology Solutions, Inc. (OTC: AITX) is a global leader in AI-driven security and productivity solutions for enterprise clients. Recently, AITX announced in its FY 2023 3rd quarter SEC filings that its quarter over quarter (Q3 over Q2) revenue increased 50%.

Following the news, the stock fell 9.23%; however, it seemed to be testing some resistance and could make a bounce back in the upcoming weeks.

In the press release, the company outlines its fiscal year 2024 goals that, if met, will result in the company’s recurring monthly revenues reaching approximately $800,000.

If the company is able to meet their expectations, it will attain positive cash flow. According to AITC, achievement of the sales goals listed will require approximately 5%-10% headcount growth in the production and deployment teams.

Keep an eye out for more market activity with AITX, as it has potential.

Northwest Biotherapeutics (OTC: NWBO) is a biotechnology company developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without the toxicities associated with chemotherapies.

Though the stock fell 0.62% on Monday to 0.72 USD, the company remains optimistic for the future. In a year-end update, the company announced that they felt 2022 had been their strongest year yet, citing three major achievements from 2022:

Reporting what NWBO believes are strong positive results from their Phase 3 clinical trial of DCVax-L for Glioblastoma brain cancer.

Having their trial results published in JAMA Oncology, a top peer-reviewed medical/scientific journal.

Commencing a major lawsuit to begin fighting back against what they believe has been manipulation of its stock.

Keep NWBO on your watchlist, as investors still seem interested in the stock.

Disclaimers: This article contains sponsored content.The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. Capital Gains Report ‘CGR’ is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. CGR authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. CGR has been compensated thirty five hundred via wire to produce and syndicate content related to VCMS. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website.